NCT03447990 - v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

October 24, 2019

Study Completion Date

October 24, 2019

Conditions

Heart Failure With Reduced Ejection FractionDilated Cardiomyopathy

Interventions

DRUG

MYK-491

Single Ascending Dose and Multiple Ascending Dose of MYK-491

DRUG

Placebo

Single Ascending Dose and Multiple Ascending Dose of placebo

Trial Locations (17)

8601

D&A Research, Sneek

10117

Charite Research Organization, Berlin

17164

Karolinska University Hospital, Stockholm

19104

University of Pennsylvania Heart and Vascular Center, Philadelphia

27710

Duke University Medical Center, Durham

32216

Jacksonville Center for Clinical Research, Jacksonville

37388

Tennessee Center for Clinical Trials, Tullahoma

43210

Ohio State University Medical Center, Columbus

55102

Prism Reseach, Saint Paul

63136

St. Louis Heart and Vascular Cardiology, St Louis

75015

Hopital Europeen Georges-Pompidou, Paris

97239

Oregon Health & Science University, Portland

07112

Newark Beth Israel Medical Center, Newark

9713 GZ

Groningen UMC, Groningen

93-513

Wojewodzki Szpital Specjalistyczny Im M Kopernika, Lodz

51-124

Wojewodzki Szpital Specjalistyczny we Wroclawiu, Oddzial Kardiologiczny z Pododdzialem Intensywnego Nadzoru Kardiologicznego i Pododdzialem Leczenia Zaburzen Rytmu Serca, Wroclaw

G51 4TF

Queen Elizabeth University Hospital, Glasgow